Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News & Events

: Press Releases

Home
News & Events
Press Releases

Press Releases

Tonix Pharmaceuticals Prices $9.0 Million Public Offering

November 15, 2019 • 8:30 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

November 8, 2019 • 4:45 PM EST

Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

November 4, 2019 • 7:00 AM EST

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

October 31, 2019 • 1:00 PM EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

October 23, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Joins the Alliance for Biosecurity

October 15, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

October 7, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

October 3, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

September 16, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

September 16, 2019 • 7:00 AM EDT

1
2
3
4
5
6
7
8
9
10
...30
Next »

News & Events : Press Releases